Management of Psoriasis Patients with Serious Infectious Diseases
AbstractThe management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C, HIV, COVID-19]. Indeed, these infections should be ruled out before starting and during systemic treatment for psoriasis. Currently, four conventional systemic drugs (methotrexate, dimethyl fumarate, acitretin, cyclosporine), four classes of biologics (anti-tumour necrosis factor alpha, anti-interleukin (IL)12/23, anti-IL-17s, and anti-IL-23], and two oral small molecules (apremilast, deucravacitinib) have been licensed for the trea...
Source: Advances in Therapy - May 6, 2024 Category: Drugs & Pharmacology Source Type: research

Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis
ConclusionThese findings demonstrate that patient adherence to and persistence with risdiplam treatment were high, including across all subgroups tested. (Source: Advances in Therapy)
Source: Advances in Therapy - May 6, 2024 Category: Drugs & Pharmacology Source Type: research

“You Take This Day by Day, Come What May”: A Qualitative Study of the Psychosocial Impacts of Living with Duchenne Muscular Dystrophy
ConclusionsFindings provide insight into the strength and resilience with which individuals and their families respond to daily challenges and major clinical milestones and highlight the relative importance of loss of upper limb function as a transition in DMD affecting health-related quality-of-life. (Source: Advances in Therapy)
Source: Advances in Therapy - May 6, 2024 Category: Drugs & Pharmacology Source Type: research

Effects of a Long-Acting Diquafosol Ophthalmic Solution on the Ocular Surface, Tolerability, and Usability in Dry Eye Disease
ConclusionThe high-viscosity DQSLX ophthalmic solution was generally considered acceptable in the study population. However, drug tolerability seemingly differed between patients with DED with and without epithelial damage. The former were affected by improvements in symptoms and clinical findings, whereas the latter were affected by comfort upon instillation.Trial RegistrationUniversity Hospital Medical Information Network identifier, UMIN000051390. (Source: Advances in Therapy)
Source: Advances in Therapy - May 6, 2024 Category: Drugs & Pharmacology Source Type: research

Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type  1 Spinal Muscular Atrophy
ConclusionLong-term data supported risdiplam as a superior alternative to nusinersen in children with type  1 SMA.Video abstract available for this article.Video abstract (MP4 184542 KB) (Source: Advances in Therapy)
Source: Advances in Therapy - May 5, 2024 Category: Drugs & Pharmacology Source Type: research

A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches
ConclusionThis model demonstrated acceptable accuracy for safety signal detection and potential for earlier detection when compared to humans. Expert judgment, flexibility, and critical thinking are essential human skills required for the final, accurate assessment of adverse event cases. (Source: Advances in Therapy)
Source: Advances in Therapy - May 5, 2024 Category: Drugs & Pharmacology Source Type: research

Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data
ConclusionsThis study is the first to use diagnosis and procedure codes from real-world Medicaid claims to document the clinical course in DMD. Findings were consistent with previously published estimates from commercially insured populations and clinical registries; and contribute to the expanding body of real-world evidence around clinical progression of patients with DMD. (Source: Advances in Therapy)
Source: Advances in Therapy - May 2, 2024 Category: Drugs & Pharmacology Source Type: research

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
AbstractAccording to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). In the open-label, single-arm, phase  2 PHAROS trial (NCT03915951), the combination of encorafenib, a potent BRAF inhibitor, and binimetinib, a potent MEK inhibitor, demonstrated durable antitumor activity with a manageable safety profile in this patient population. On the basis of the results of this study, the combination of encoraf enib plus binimetinib was approved by the US Food and Drug Adminis...
Source: Advances in Therapy - May 2, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6  Months to 5 Years with Severe Atopic Dermatitis
(Source: Advances in Therapy)
Source: Advances in Therapy - May 2, 2024 Category: Drugs & Pharmacology Source Type: research

Pharmacological Basis of Differences in Dose Response, Dose Equivalence, and Duration of Action of Inhaled Corticosteroids
ConclusionIn a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research

Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes
ConclusionsPrescribing more efficacious treatments earlier provides a greater opportunity to improve patient outcomes and minimizes treatment failures. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research

Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis
ConclusionNearly half of the patients initiating vibegron were adherent. Factors associated with adherence and persistence were more likely to be related to prescribing practices than patient characteristics. These results suggest it may be best to follow up with patients approximately 4  to 5 months after initiating treatment with vibegron. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research

The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs
ConclusionThese analyses support the use of precision epigenetic methods as part of the initial diagnosis and care of stable CHD and can meaningfully reduce cost. Real-world pilots to test the reliability of these analyses are indicated. (Source: Advances in Therapy)
Source: Advances in Therapy - April 25, 2024 Category: Drugs & Pharmacology Source Type: research

Development and Application of an Attribute-Based Taxonomy on the Benefits of Oral Anticoagulant Switching in Atrial Fibrillation: A Delphi Study
ConclusionsThe Delphi-based taxonomy identified five criteria for the beneficial effects of OAC switching, aiding in characterizing real-world OAC switching. (Source: Advances in Therapy)
Source: Advances in Therapy - April 24, 2024 Category: Drugs & Pharmacology Source Type: research

Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn ’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study
ConclusionsSubpopulations of biologic-naive patients with CD in whom vedolizumab appeared to have a larger effect relative to anti-TNF α agents for the outcome of clinical remission were identified. Validation of the identified subpopulations and simplified rules are warranted to confirm these findings.ClinicalTrials.gov IdentifierNCT03710486.Graphical Abstract available for this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - April 24, 2024 Category: Drugs & Pharmacology Source Type: research